• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中性粒细胞减少症的癌症化疗患儿出现发热且无严重疾病时,抗生素使用时间与临床结局无关。

Time to antibiotics is unrelated to outcome in pediatric patients with fever in neutropenia presenting without severe disease during chemotherapy for cancer.

机构信息

Pediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Switzerland.

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

出版信息

Sci Rep. 2022 Aug 18;12(1):14028. doi: 10.1038/s41598-022-18168-x.

DOI:10.1038/s41598-022-18168-x
PMID:35982121
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9388602/
Abstract

Fever in neutropenia (FN) remains an unavoidable, potentially lethal complication of chemotherapy. Timely administration of empirical broad-spectrum intravenous antibiotics has become standard of care. But the impact of time to antibiotics (TTA), the lag period between recognition of fever or arrival at the hospital to start of antibiotics, remains unclear. Here we aimed to analyze the association between TTA and safety relevant events (SRE) in data from a prospective multicenter study. We analyzed the association between time from recognition of fever to start of antibiotics (TTA) and SRE (death, admission to intensive care unit, severe sepsis and bacteremia) with three-level mixed logistic regression. We adjusted for possible triage bias using a propensity score and stratified the analysis by severity of disease at presentation with FN. We analyzed 266 FN episodes, including 53 (20%) with SRE, reported in 140 of 269 patients recruited from April 2016 to August 2018. TTA (median, 120 min; interquartile range, 49-180 min) was not associated with SRE, with a trend for less SREs in episodes with longer TTA. Analyses applying the propensity score suggested a relevant triage bias. Only in patients with severe disease at presentation there was a trend for an association of longer TTA with more SRE. In conclusion, TTA was unrelated to poor clinical outcome in pediatric patients with FN presenting without severe disease. We saw strong evidence for triage bias which could only be partially adjusted.

摘要

中性粒细胞减少症(FN)并发发热是化疗不可避免的、潜在致命的并发症。及时给予经验性广谱静脉内抗生素治疗已成为常规护理。但抗生素治疗时间(TTA),即从发热或到达医院开始使用抗生素的时间到开始使用抗生素的时间之间的时间差,其影响仍不清楚。在这里,我们旨在分析前瞻性多中心研究数据中 TTA 与安全相关事件(SRE)之间的关联。我们使用三级混合逻辑回归分析了从发热识别到开始使用抗生素(TTA)的时间与 SRE(死亡、入住重症监护病房、严重败血症和菌血症)之间的关联。我们使用倾向评分调整了可能的分诊偏倚,并根据 FN 时疾病的严重程度对分析进行分层。我们分析了 266 例 FN 发作,包括 140 例 269 例患者中报告的 53 例(20%)有 SRE。从 2016 年 4 月至 2018 年 8 月招募的 FN 患者中报告的 53 例(20%)有 SRE。TTA(中位数 120 分钟;四分位距 49-180 分钟)与 SRE 无关,TTA 较长的发作 SRE 较少。应用倾向评分的分析表明存在相关的分诊偏倚。仅在首发疾病严重的患者中,较长的 TTA 与更多的 SRE 呈趋势相关。总之,在没有严重疾病的 FN 儿科患者中,TTA 与不良临床结局无关。我们看到了强烈的分诊偏倚证据,只能部分调整。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e5/9388602/01ce0ba6003c/41598_2022_18168_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e5/9388602/a2a73b65f1af/41598_2022_18168_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e5/9388602/316cd2121f36/41598_2022_18168_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e5/9388602/f2803d62ce13/41598_2022_18168_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e5/9388602/01ce0ba6003c/41598_2022_18168_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e5/9388602/a2a73b65f1af/41598_2022_18168_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e5/9388602/316cd2121f36/41598_2022_18168_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e5/9388602/f2803d62ce13/41598_2022_18168_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e5/9388602/01ce0ba6003c/41598_2022_18168_Fig4_HTML.jpg

相似文献

1
Time to antibiotics is unrelated to outcome in pediatric patients with fever in neutropenia presenting without severe disease during chemotherapy for cancer.中性粒细胞减少症的癌症化疗患儿出现发热且无严重疾病时,抗生素使用时间与临床结局无关。
Sci Rep. 2022 Aug 18;12(1):14028. doi: 10.1038/s41598-022-18168-x.
2
Predicting fever in neutropenia with safety-relevant events in children undergoing chemotherapy for cancer: The prospective multicenter SPOG 2015 FN Definition Study.预测癌症化疗中性粒细胞减少症患儿的发热:前瞻性多中心 SPOG 2015 FN 定义研究。
Pediatr Blood Cancer. 2021 Dec;68(12):e29253. doi: 10.1002/pbc.29253. Epub 2021 Jul 26.
3
Protocol for a systematic review of time to antibiotics (TTA) in patients with fever and neutropenia during chemotherapy for cancer (FN) and interventions aiming to reduce TTA.发热伴中性粒细胞减少的癌症化疗患者使用抗生素的时间(TTA)的系统评价方案,以及旨在缩短 TTA 的干预措施。
Syst Rev. 2019 Apr 3;8(1):82. doi: 10.1186/s13643-019-1006-8.
4
A prospective multicenter study of microbiologically defined infections in pediatric cancer patients with fever and neutropenia: Swiss Pediatric Oncology Group 2003 fever and neutropenia study.一项针对发热且中性粒细胞减少的儿科癌症患者微生物学确诊感染的前瞻性多中心研究:瑞士儿科肿瘤学组2003年发热与中性粒细胞减少研究
Pediatr Infect Dis J. 2014 Sep;33(9):e219-25. doi: 10.1097/INF.0000000000000326.
5
[Time to Antibiotics (TTA) - Reassessment from the German Working Group for Fever and Neutropenia in Children and Adolescents (DGPI/GPOH)].[抗生素使用时机(TTA)——德国儿童和青少年发热与中性粒细胞减少工作组(DGPI/GPOH)的重新评估]
Klin Padiatr. 2023 Nov;235(6):331-341. doi: 10.1055/a-2135-4210. Epub 2023 Sep 26.
6
39·0°C versus 38·5°C ear temperature as fever limit in children with neutropenia undergoing chemotherapy for cancer: a multicentre, cluster-randomised, multiple-crossover, non-inferiority trial.39.0°C 与 38.5°C 耳温作为中性粒细胞减少症癌症化疗患儿发热界限:一项多中心、整群随机、多次交叉、非劣效性试验。
Lancet Child Adolesc Health. 2020 Jul;4(7):495-502. doi: 10.1016/S2352-4642(20)30092-4. Epub 2020 Jun 1.
7
Association of time to antibiotics and clinical outcomes in patients with fever and neutropenia during chemotherapy for cancer: a systematic review.癌症化疗期间发热伴中性粒细胞减少症患者使用抗生素的时间与临床结局的关系:系统评价。
Support Care Cancer. 2020 Mar;28(3):1369-1383. doi: 10.1007/s00520-019-04961-4. Epub 2019 Jul 1.
8
Outcome prediction in pediatric fever in neutropenia: Development of clinical decision rules and external validation of published rules based on data from the prospective multicenter SPOG 2015 FN definition study.中性粒细胞减少症儿童发热的预后预测:基于前瞻性多中心 SPOG 2015 FN 定义研究数据,制定临床决策规则并对已发表规则进行外部验证。
PLoS One. 2023 Aug 2;18(8):e0287233. doi: 10.1371/journal.pone.0287233. eCollection 2023.
9
Patient Outcomes With Febrile Neutropenia Based on Time to Antibiotics in the Emergency Department.基于急诊科抗生素使用时间的发热性中性粒细胞减少症患者结局。
Pediatr Emerg Care. 2022 Jan 1;38(1):e259-e263. doi: 10.1097/PEC.0000000000002241.
10
Time to antibiotic administration in children with febrile neutropenia: Report from a low middle-income country.发热性中性粒细胞减少症患儿应用抗生素的时间:来自中低收入国家的报告。
Indian J Med Res. 2021 Apr;154(4):615-622. doi: 10.4103/ijmr.IJMR_2483_19.

引用本文的文献

1
Prevention and Management of Infectious Complications in Pediatric Patients With Cancer: A Survey Assessment of Current Practices Across Children's Oncology Group Institutions.癌症患儿感染并发症的预防与管理:儿童肿瘤协作组机构当前实践的调查评估
Pediatr Blood Cancer. 2025 Mar;72(3):e31532. doi: 10.1002/pbc.31532. Epub 2025 Jan 8.
2
Impact of time to antibiotics on clinical outcome in paediatric febrile neutropenia: a target trial emulation of 1685 episodes.抗生素使用时间对儿童发热性中性粒细胞减少症临床结局的影响:1685例病例的目标试验模拟
Lancet Reg Health West Pac. 2024 Nov 2;53:101226. doi: 10.1016/j.lanwpc.2024.101226. eCollection 2024 Dec.
3

本文引用的文献

1
Predicting fever in neutropenia with safety-relevant events in children undergoing chemotherapy for cancer: The prospective multicenter SPOG 2015 FN Definition Study.预测癌症化疗中性粒细胞减少症患儿的发热:前瞻性多中心 SPOG 2015 FN 定义研究。
Pediatr Blood Cancer. 2021 Dec;68(12):e29253. doi: 10.1002/pbc.29253. Epub 2021 Jul 26.
2
8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation.第八届欧洲白血病感染会议:2020 年儿童癌症或造血细胞移植后患者抗生素使用指南。
Lancet Oncol. 2021 Jun;22(6):e270-e280. doi: 10.1016/S1470-2045(20)30725-7. Epub 2021 Mar 31.
3
Impact of Time-to-Antibiotic Delivery in Pediatric Patients With Cancer Presenting With Febrile Neutropenia.
癌症合并发热性中性粒细胞减少症患儿抗生素给药时间的影响。
JCO Oncol Pract. 2024 Feb;20(2):228-238. doi: 10.1200/OP.23.00583. Epub 2023 Dec 21.
4
Barriers to and facilitators of effective management of fever episodes in hospitalised Kenyan children with cancer: protocol for convergent mixed methods study.肯尼亚癌症住院儿童发热管理障碍及促进因素的研究方案:收敛混合方法研究。
BMJ Open. 2023 Nov 2;13(11):e078124. doi: 10.1136/bmjopen-2023-078124.
Improving Antibiotic Timing in Febrile Neutropenia for Pediatric Oncology Patients with a Central Line.
改善有中央静脉置管的儿科肿瘤患者中性粒细胞减少性发热时的抗生素时机
J Pediatr Oncol Nurs. 2021 May-Jun;38(3):185-189. doi: 10.1177/1043454221992294. Epub 2021 Feb 22.
4
Improving management of fever in neutropenic children with cancer across multiple sites.改善多个地点癌症中性粒细胞减少症儿童发热的管理。
Eur J Cancer Care (Engl). 2021 May;30(3):e13413. doi: 10.1111/ecc.13413. Epub 2021 Jan 28.
5
39·0°C versus 38·5°C ear temperature as fever limit in children with neutropenia undergoing chemotherapy for cancer: a multicentre, cluster-randomised, multiple-crossover, non-inferiority trial.39.0°C 与 38.5°C 耳温作为中性粒细胞减少症癌症化疗患儿发热界限:一项多中心、整群随机、多次交叉、非劣效性试验。
Lancet Child Adolesc Health. 2020 Jul;4(7):495-502. doi: 10.1016/S2352-4642(20)30092-4. Epub 2020 Jun 1.
6
Interventions aiming to reduce time to antibiotics (TTA) in patients with fever and neutropenia during chemotherapy for cancer (FN), a systematic review.旨在减少癌症化疗期间发热伴中性粒细胞减少症(FN)患者抗生素使用时间(TTA)的干预措施:系统评价。
Support Care Cancer. 2020 May;28(5):2369-2380. doi: 10.1007/s00520-019-05056-w. Epub 2019 Sep 5.
7
Association of time to antibiotics and clinical outcomes in patients with fever and neutropenia during chemotherapy for cancer: a systematic review.癌症化疗期间发热伴中性粒细胞减少症患者使用抗生素的时间与临床结局的关系:系统评价。
Support Care Cancer. 2020 Mar;28(3):1369-1383. doi: 10.1007/s00520-019-04961-4. Epub 2019 Jul 1.
8
Protocol for a systematic review of time to antibiotics (TTA) in patients with fever and neutropenia during chemotherapy for cancer (FN) and interventions aiming to reduce TTA.发热伴中性粒细胞减少的癌症化疗患者使用抗生素的时间(TTA)的系统评价方案,以及旨在缩短 TTA 的干预措施。
Syst Rev. 2019 Apr 3;8(1):82. doi: 10.1186/s13643-019-1006-8.
9
Impact of time to antibiotic on hospital stay, intensive care unit admission, and mortality in febrile neutropenia.发热性中性粒细胞减少症中抗生素使用时间对住院时间、重症监护病房入住率和死亡率的影响。
Support Care Cancer. 2019 Nov;27(11):4171-4177. doi: 10.1007/s00520-019-04701-8. Epub 2019 Feb 25.
10
Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update.儿童癌症和造血干细胞移植受者发热与中性粒细胞减少管理指南:2017 年更新版。
J Clin Oncol. 2017 Jun 20;35(18):2082-2094. doi: 10.1200/JCO.2016.71.7017. Epub 2017 May 1.